Overview

RituxiMab INDuction in Renal Transplantation

Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Hypothesis: - That B cell depletion, rather than reducing acute rejection, will allow minimisation of immunosuppression, which may lead to better graft survival. Aim: - To assess whether the addition of rituximab to a low-dose tacrolimus immunosuppression regime allows a reduction in steroid administration. Objectives: - To assess whether B cell depletion affects graft function, acute rejection and complication rates - To assess whether the T cell response to allotransplantation is impaired by B cell depletion.
Phase:
Phase 4
Details
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborator:
Astellas Pharma Europe Ltd.
Treatments:
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rituximab
Tacrolimus